Designing effective vaccines to extend life expectancy

All licensed vaccines that have an adjuvant are susceptible to irreversible damage upon exposure to freezing or warm temperatures and must be kept at 2-8 oC through a cold supply chain. About 33-37% of these vaccines are exposed to freezing temperatures due to malfunction in refrigerators or during transportation.

Engimata has a platform adjuvant technology (L-Vac) that improves vaccine efficiency.

Engimata is currently developing a vaccine against COVID-19 using its platform technology. Engimata’s vaccine is cost-effective, easy to scale up, and simple to manufacture and distribute outside the cold supply chain. This increases vaccine accessibility and stability, ultimately saving cost, resources, and lives.

Engimata’s platform technology is improving vaccine efficiency and stability across a wide temperature range.

It is compatible with recombinant protein antigens and it enhances the immune response required for vaccines against diseases such as influenza, SARS, AIDS, and COVID-19.